ArticleFrontiers in immunology2017
U-Omp19 from
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Flipping the script: Using mucosal immune obstacles to inform vaccine design.PLoS pathogens · 2026Article
- Discovery of protease inhibitors from bacteria as novel adjuvants for oral vaccine formulations.Frontiers in immunology · 2025Article
- The recent advances in vaccine adjuvants.Frontiers in immunology · 2025Review
- Pal Affects the Proliferation in Macrophages and Virulence of Brucella, and as Mucosal Adjuvants, Provides an Effective Protection to Mice Against Salmonella Enteritidis.Current microbiology · 2022Article
- A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.Frontiers in immunology · 2022Article
- A disordered region retains the full protease inhibitor activity and the capacity to induce CD8Computational and structural biotechnology journal · 2022Article
- A novel oral rabies vaccine enhances the immunogenicity through increasing dendritic cells activation and germinal center formation by expressing U-OMP19 in a mouse model.Emerging microbes & infections · 2021Article
- Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.Veterinary research · 2021Article
- Stability Studies of the Vaccine Adjuvant U-Omp19.Journal of pharmaceutical sciences · 2021Article
- Article
- Protective efficacy of the recombinant lysozyme-PMAP36 fusion protein-inactivatedCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2020Article
- Selection of adjuvants for vaccines targeting specific pathogens.Expert review of vaccines · 2019Review
- Oral co-administration of a bacterial protease inhibitor in the vaccine formulation increases antigen delivery at the intestinal epithelial barrier.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Glycyrrhizin AttenuatesFrontiers in immunology · 2018Article
- Protective efficacy of aCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Most pathogens infect through mucosal surfaces, and parenteral immunization typically fails to induce effective immune responses at these sites. Development of oral-administered vaccines capable of inducing mucosal as well as systemic immunity while bypassing the issues of antigen degradation and immune tolerance could be crucial for the control of enteropathogens. This study demonstrates that U-Omp19, a bacterial protease inhibitor with immunostimulatory features, coadministered with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.